BIOLAN HEALTH, in collaboration with HOSPITAL QUIRÓNSALUD BIZKAIA, launches in the Basque Country a new test for the early detection of lactose intolerance

06 October 2022

Healthcare

On September 26, the Basque companies BIOLAN HEALTH and HOSPITAL QUIRÓNSALUD BIZKAIA, in collaboration with VENTER PHARMA, presented a new urine test for the early detection of lactose intolerance in a simple and reliable way. Lactose intolerance affects, according to the Spanish Digestive System Foundation, between 20% and 40% of our population and is caused by the lack of an enzyme called intestinal lactase, causing nausea, abdominal pain or diarrhea in these patients.

Until now, testing for lactose intolerance consisted of having the patient ingest a lactose-containing preparation and then having a blood test or a hydrogen breath test, an action that is uncomfortable for the patient. However, the development of BIOLAN HEALTH's OSAXYL biosensor, together with VENTAR PHARMA's LACTEST drug, offers a disruptive solution for detecting this intolerance more quickly and safely, an innovation on which QUIRONSALUD Hospital of Bizkaia is committed.

People with hypolactasia, as this disease is called, have various symptoms after ingesting lactose-containing products, ranging from abdominal pain, gas and diarrhea to vomiting, but the symptoms vary depending on the amount ingested and the level of intolerance. For this reason, the launch of this shared initiative will be implemented at QUIRÓNSALUD Bizkaia Hospital, offering the center's patients this diagnostic test, and expecting satisfactory results very soon.

This joint initiative has been propitiated as a result of the implementation of theOSASUNBERRI project, which aims to facilitate a collaborative environment for innovation among companies in the health sector. The objective of OSASUNBERRI is to join forces and strengthen the Km 0 health sector, with the development and incorporation of innovative solutions in the health system and investment in competitive research and production infrastructures.